[{"id":"6cd3b965-1498-4a7b-8e52-1d5006e1cb85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05322850","created_at":"2022-04-12T14:52:55.429Z","updated_at":"2024-07-02T16:34:26.410Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)","source_id_and_acronym":"NCT05322850","lead_sponsor":"University of Florida","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OrcaGraft (engineered donor allograft cell therapy)"],"overall_status":"Suspended","enrollment":" Enrollment 40","initiation":"Initiation: 08/16/2022","start_date":" 08/16/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-06-13"}]